Clinical Research Focus 28th Edition May | Cromos Pharma
Clinical Research Focus. 28th Edition Anticipating ASCO: Key Trends in Oncology Clinical Research The upcoming ASCO Conference, an essential gathering for oncology professionals, where leading experts will discuss the latest advancements in cancer research and treatment. Cromos Pharma’s CEO, Vlad Bogin, will attend to share his insights. In his new article, Dr. Bogin explores innovative trends and future directions in Read more
Clinical Trials in Ukraine 2024 | Cromos Pharma
Ukraine Strives to Remain a Hub for Clinical Trials Despite Conflict In the last couple of decades Ukraine had established itself as a thriving hub for clinical trials, especially recognized for its advancements in oncology research. Before the conflict began, the country was a beacon for international medical research, attracting increasing number of studies each year. However, the onset of the war significantly slowed this activity, Read more
Meet Vlad Bogin at the ASCO Annual Meeting 2024 | Cromos Pharma
Anticipating ASCO: Key Trends in Oncology Clinical Research As we approach the American Society of Clinical Oncology (ASCO) conference, the oncology community is abuzz with anticipation. Recognized as a premier event in the field, ASCO serves as a critical platform for presenting groundbreaking research, discussing innovative treatments, and sharing advancements that shape the future of cancer care. The significance of ASCO is underscored Read more
Rezdiffra Approval | Cromos Pharma
Rezdiffra Approval Sheds Light on the Challenges of NASH Diagnosis and Fibrosis Identification The recent approval of Rezdiffra (resmetirom), a novel therapeutic for the treatment of non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, marks a significant milestone in the fight against this increasingly prevalent liver disease. However, the journey to this point underscores the persistent challenges faced by healthcare professionals in diagnosing NASH and identifying fibrosis Read more